Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2012-11-07 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Exercise of Employee Options 11 pages 95.1KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class, number, terms, issue price, purpose, and dates related to the securities. It references ASX rules and includes a quotation agreement for listing the new securities on the ASX. The content is consistent with a formal announcement of new share issues and related capital changes rather than a full financial report or earnings release. There is no financial statement or management discussion, nor is it a regulatory certification or voting result. The document fits the definition of a 'Share Issue/Capital Change' announcement.
2012-11-07 English
Appendix 3B - Option Exercise 11 pages 95.1KB
Capital/Financing Update Classification · 95% confidence The document is an Appendix 3B form, which is a standard ASX (Australian Securities Exchange) announcement used to notify the market of a new issue of securities, application for quotation of additional securities, or agreement related to securities. The content details the issuance of fully paid ordinary shares upon exercise of options under an employee option plan, including the number of shares, exercise price, and dates. This type of document is a capital/financing update as it relates to changes in the company's capital structure through share issuance. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of a report publication. Therefore, the correct classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed securities information support this classification with high confidence.
2012-10-29 English
Trading Halt 2 pages 45.0KB
Regulatory Filings Classification · 95% confidence The document is a market release dated 26 October 2012 from Pharmaxis Ltd requesting a trading halt of its securities pending an announcement related to the release of a Final Appraisal Determination by NICE. The text is short (2149 characters) and primarily serves as a notification to the exchange and market about the trading halt and the reason for it. There is no financial data, report content, or detailed announcement included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like financial reports or earnings releases.
2012-10-25 English
IMPORTANT MILESTONE BRONCHITOL APPROVED BY NICE IN UK 2 pages 88.6KB
Regulatory Filings Classification · 95% confidence The document is a media release announcing a positive recommendation by the UK's National Institute for Health and Clinical Excellence (NICE) for the pharmaceutical product Bronchitol. It discusses regulatory approval milestones, clinical benefits, and company statements but does not contain financial data, detailed financial performance, or comprehensive report content. It is not an annual or interim report, earnings release, or any form of financial filing. The document is a public announcement of a regulatory milestone and product approval, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2012-10-25 English
Results of Meeting 2 pages 82.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a letter addressed to the Australian Securities Exchange regarding the outcomes of resolutions at the Annual General Meeting (AGM) of Pharmaxis Ltd held on 17 October 2012. It details the voting results on various resolutions such as the remuneration report, re-election of directors, grant of performance rights and options, and renewal of takeover provisions. The document is focused on reporting the official results of shareholder votes at the AGM, including proxy votes and whether motions were carried. It does not contain the full AGM materials or presentations, nor is it an announcement of a report publication. The content matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is 4018 characters, which is consistent with a detailed voting results announcement rather than a full report or presentation. Therefore, the correct classification is DVA with high confidence.
2012-10-17 English
Appendix 3B - Option Issue 12 pages 103.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of unlisted employee options and performance rights, including terms, quantities, and conditions. The document references ASX rules and includes detailed information about securities issued, their exercise prices, expiry dates, and vesting conditions. This type of document is a formal announcement related to new share issues or capital changes rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the securities issued. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2012-10-17 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.